| 000 | 01738 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516022726.0 | ||
| 264 | 0 | _c20111222 | |
| 008 | 201112s 0 0 eng d | ||
| 022 | _a1742-1241 | ||
| 024 | 7 |
_a10.1111/j.1742-1241.2011.02633.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGrosso, A M | |
| 245 | 0 | 0 |
_aComparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. _h[electronic resource] |
| 260 |
_bInternational journal of clinical practice _cMar 2011 |
||
| 300 |
_a253-63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Review; Systematic Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xeconomics |
| 650 | 0 | 4 |
_aBenzimidazoles _xeconomics |
| 650 | 0 | 4 | _aBiphenyl Compounds |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Failure _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 |
_aLosartan _xeconomics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTetrazoles _xeconomics |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aBodalia, P N | |
| 700 | 1 | _aMacallister, R J | |
| 700 | 1 | _aHingorani, A D | |
| 700 | 1 | _aMoon, J C | |
| 700 | 1 | _aScott, M A | |
| 773 | 0 |
_tInternational journal of clinical practice _gvol. 65 _gno. 3 _gp. 253-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1742-1241.2011.02633.x _zAvailable from publisher's website |
| 999 |
_c20563992 _d20563992 |
||